Nitrofurantoin Monohyd/M-Cryst
Brand name: Nitrofurantoin Mono-Macro
Rank #386 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$24.4M
Total Cost
1,173,249
Total Claims
$24.4M
Total Cost
45,497
Prescribers
$21
Cost per Claim
860,796
Beneficiaries
1,225,499
30-Day Fills
$537
Avg Cost/Provider
26
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$24.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $24.4M total
Top Prescribers of Nitrofurantoin Monohyd/M-Cryst
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Edward Hayes | Urology | Dublin, GA | 458 | $27K |
| 2 | William Bundrick | Urology | Bossier City, LA | 289 | $23K |
| 3 | Griselda Cheng-Akwa | Nurse Practitioner | Lexington, KY | 333 | $21K |
| 4 | Scott Macdiarmid | Urology | Greensboro, NC | 454 | $20K |
| 5 | Steven Jensen | Urology | Saginaw, MI | 591 | $20K |
| 6 | Glenn Kershen | Urology | Saginaw, MI | 338 | $19K |
| 7 | Igor Ryndin | Urology | Brooklyn, NY | 508 | $16K |
| 8 | Hatshepsut Oshun | Physician Assistant | Denton, TX | 869 | $15K |
| 9 | Alexander Gershman | Urology | Los Angeles, CA | 531 | $15K |
| 10 | Rowena Desouza | Urology | Cordova, TN | 486 | $15K |
| 11 | William Roth | Urology | Lafayette, LA | 352 | $14K |
| 12 | Frank Bacque | Urology | Lafayette, LA | 263 | $14K |
| 13 | Mark Byron | Urology | Jesup, GA | 545 | $13K |
| 14 | Christopher Steidle | Urology | Corbin, KY | 194 | $13K |
| 15 | Elizabeth Kavaler | Urology | New York, NY | 755 | $13K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 383 | Flecainide Acetate (Flecainide Acetate) | $25.1M | 412,334 |
| 384 | Pioglitazone Hcl (Pioglitazone Hcl) | $24.8M | 1,182,614 |
| 385 | Fremanezumab-Vfrm (Ajovy Autoinjector) | $24.7M | 29,389 |
| 386 | Nitrofurantoin Monohyd/M-Cryst (Nitrofurantoin Mono-Macro) | $24.4M | 1,173,249 |
| 387 | Pegfilgrastim (Neulasta) | $24.4M | 3,096 |
| 388 | Linagliptin/Metformin Hcl (Jentadueto) | $24.3M | 33,018 |
| 389 | Ocrelizumab (Ocrevus) | $24.2M | 639 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology